Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 14-19, January 2004

Logistics of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)

  • A.Michael Zimmer

      Affiliations

    • Department of Nuclear Medicine, Northwestern Memorial Hospital, Chicago, IL, USA
    • *Address reprint requests to A. Michael Zimmer, PhD, Nuclear Medicine Department, Northwestern Memorial Hospital, Galter Pavilion, 8th Floor, 251 E Huron, Chicago, IL 60611, USA
    • 1Dr Zimmer has received honoraria from Biogen Idec, Inc.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0001-2998(03)00078-3

doi:10.1053/j.semnuclmed.2003.11.001

Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 14-19, January 2004

Article Tools

* Image Usage & Resolution